J&J bolsters emerging markets presence with first Chinese acquisition
This article was originally published in Clinica
Johnson & Johnson has strengthened its position in China by making its maiden acquisition there, buying fibrin sealant developer Guangzhou Bioseal Biotechnology. The privately-held firm, founded in 1995, has developed a porcine plasma-derived biologic product, Bioseal, designed to help control bleeding during surgery. It is the only porcine plasma-based fibrin sealant to be approved in China, the company claims.